Immune function in transgenic mice overexpressing growth hormone (GH) releasing hormone, GH or GH antagonist.
Effects of life-long exposure to high levels of homologous or heterologous growth hormone (GH) and effects of GH resistance on selected parameters of immune function were studied in adult male transgenic mice overexpressing GH releasing hormone (GHRH), bovine (b) GH or an antagonistic bGH analog. In metallothionein I (MT)-bGH transgenic mice with high peripheral levels of bovine GH, there were significant increases in the absolute weight of the thymus and the spleen and in the mitogenic responses of splenocytes to concanavalin A (ConA), lipopolysaccharide (LPS) and phytohemagglutinin (PHA), as compared to age-matched normal animals. There were no significant differences between MT-bGH transgenic and normal mice in splenocyte viability or in delayed-type hypersensitivity measured by the allergic contact dermatitis response to oxazolone. Similar results, including significant stimulation of splenocyte responses to ConA, LPS, and PHA, were obtained in MT-hGHRH transgenic mice in which overexpression of GHRH leads to striking pituitary enlargement and massive elevation of peripheral levels of homologous (mouse) GH. In MT-bGH-antagonist transgenic mice in which overexpression of an antagonistic bGH analog interferes with the actions of endogenous GH, spleen weight was reduced but proliferative responses of splenocytes to ConA, LPS, and PHA were not affected. It is concluded that overexpression of heterologous or homologous GH in transgenic mice can lead to significant stimulation of some parameters of immune function, whereas antagonism of GH action by expression of an antagonistic GH analog does not affect splenocyte responses to mitogens.
Dialynas
E
E
Department of Physiology, Southern Illinois University, Carbondale, Illinois 62901-6512, USA.
Brown-Borg
H
H
Bartke
A
A
D000172:Acromegaly / Q000235:genetics; D000818:Animals; D001835:Body Weight / Q000235:genetics; D002352:Carrier Proteins; D002417:Cattle; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D005786:Gene Expression Regulation; D013006:Growth Hormone / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000276:immunology; D008297:Male; D008668:Metallothionein / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D008934:Mitogens / Q000494:pharmacology; D009929:Organ Size / Q000235:genetics; D010081:Oxazolone; D011401:Promoter Regions, Genetic; D013154:Spleen / Q000276:immunology
D002352:Carrier Proteins; D008934:Mitogens; D010081:Oxazolone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D008668:Metallothionein; C051815:somatotropin-binding protein